

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:
Roy R. Lobb

Application No.: 10/521,513

Confirmation No.: 2848

Filed: November 18, 2005

Art Unit: 1647

For: THERAPIES FOR
GLUMERULONEPHRITIS USING
INTERFERON-BETA-1 (as amended)

Examiner: J. Seharaseyon

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT

MS RCE
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Dear Examiner:

In accordance with C.F.R. § 1.97(b)(4), Applicant hereby brings to the Examiner's attention the references listed on the accompanying form PTO/SB/08. Pursuant to 37 C.F.R. § 1.98(2)(ii), Applicant has not enclosed copies of the cited U.S. patents or published applications. Applicant respectfully requests that the Examiner consider the listed documents and indicate that they were considered by making appropriate notations on the attached form. Applicant submits that the English language abstracts of references CD and CE satisfies the requirement for providing a concise explanation of a non-English language reference pursuant to M.P.E.P. § 609.04(a).

Applicant has listed dates of publication on the attached PTO/SB/08 for the cited documents based on information presently available to the undersigned. The listed publication dates, however, should not be construed that the information in the cited documents was actually published or otherwise publicly available on the date indicated.

This submission does not represent that a search has been made or that no better art exists. Nor does it constitute an admission that each or all of the listed documents are material or constitute “prior art.” Further, if the Examiner applies any of the documents as prior art against any claim in the application and Applicant determines that the cited documents do not constitute “prior art” under United States law, Applicant reserves the right to present to the Office the relevant facts and law regarding the appropriate status of such documents. Moreover, Applicant further reserves the right to take appropriate action to establish the patentability of the disclosed invention over the listed documents, should one or more of the documents be applied against the claims of the present application.

In accordance with 37 C.F.R. §§ 1.97(b)(4) and 1.114(c), this Information Disclosure Statement is being filed with a Request for Continued Examination, and thus, prior to the mailing of a first Office Action on the merits after the filing of a Request for Continued Examination. Therefore, no fee is believed to be due in connection with this submission. Nevertheless the Commissioner is authorized to charge any deficiencies or credit any overpayment to/from our **Deposit Account No. 06-1448, Reference BII-001.01.**

Dated: July 15, 2010

Respectfully submitted,

/Beth E. Arnold/

Beth E. Arnold

Registration No.: 35,430

FOLEY HOAG LLP

155 Seaport Blvd

Boston, Massachusetts 02210

(617) 832-1294

Attorney for Applicants